This suggests that the blood T-cell profile observed in high tumor burden FL patients could be at least partially reverted by rituximab-based treatment, and that anti-tumor activity could be reinforced by an increase in the number of CD4+ TCM, CD8+ TCM and CD8+ TN. This evidence concerns the gene CD8A and neoplasm.